Arrivent BioPharma, Inc. (AVBP)
16.00
-0.46
(-2.79%)
USD |
NASDAQ |
Oct 13, 14:53
Arrivent BioPharma Total Liabilities (Quarterly) : 27.88M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.88M |
| March 31, 2026 | 25.32M |
| December 31, 2025 | 25.94M |
| September 30, 2025 | 21.56M |
| June 30, 2025 | 19.64M |
| March 31, 2025 | 12.95M |
| December 31, 2024 | 17.29M |
| September 30, 2024 | 15.22M |
| Date | Value |
|---|---|
| June 30, 2024 | 12.20M |
| March 31, 2024 | 10.12M |
| December 31, 2023 | 11.80M |
| September 30, 2023 | 10.10M |
| June 30, 2023 | 12.81M |
| March 31, 2023 | |
| December 31, 2022 | 8.371M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 394.72M |
| Shareholders Equity (Quarterly) | 366.84M |
| Debt to Equity Ratio | 0.001 |
| Current Ratio | 14.16 |
| Net Debt Paydown Yield | 0.00% |